Active Ingredient History
Rilotumumab is a human monoclonal antibody designed for the treatment of solid tumors. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Renal Cell (Phase 2)
Colonic Neoplasms (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 1/Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Hamartoma (Phase 2)
Lung Neoplasms (Phase 3)
Mesothelioma (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 1/Phase 2)
Proto-Oncogene Proteins c-met (Phase 3)
Rectal Neoplasms (Phase 1/Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Stomach Neoplasms (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue